Mr. Robert Andrade reports

FENNEC PHARMACEUTICALS TO REPORT FULL YEAR AND FOURTH QUARTER 2024 FINANCIAL RESULTS ON MARCH 10, 2025

Fennec Pharmaceuticals Inc. will release its full year and fourth quarter 2024 financial results before the opening of the United States financial markets on Monday, March 10, 2025. Management will host a conference call and webcast that day to discuss the company's financial and business results.

Conference call and webcast detail

Date:  Monday, March 10, 2025

Time:  8:30 a.m. Eastern Time

To access the live webcast link, log onto the company website and proceed to the news and events/event calendar page under the investors and media heading. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on the company website for 30 days.

About Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of Pedmark to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, Pedmark received FDA approval in September, 2022, and European Commission approval in June, 2023, and United Kingdom approval in October, 2023, under the brand name Pedmarqsi. Pedmark has received orphan drug exclusivity in the United States and Pedmarqsi has received pediatric use marketing authorization in Europe, which includes eight years plus two years of data and market protection.